Reasons for combining immunotherapy with chemo to enhance anti tumour response

Prof Angus Dalgleish - St George's, University of London, London, UK
Reasons for combining immunotherapy with chemo to enhance anti tumour response ( Prof Angus Dalgleish - St George's, University of London, London, UK )
25 Mar 2014

Dendritic cell vaccination combined with CTLA4 blockade

Dr Kris Thielemans - Medical School of the VUB, Brussels, Belgium
Dendritic cell vaccination combined with CTLA4 blockade ( Dr Kris Thielemans - Medical School of the VUB, Brussels, Belgium )
25 Mar 2014

ecancermedicalscience Editor's Choice for January 2014

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy
ecancermedicalscience Editor's Choice for January 2014 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )
12 Feb 2014

Where to next for the elderly with acute myeloid leukaemia?

Dr Uwe Platzbecker - University Hospital Dresden, Germany and Prof Gert Ossenkoppele - VU University Medical Center, Amsterdam, Netherlands
Where to next for the elderly with acute myeloid leukaemia? ( Dr Uwe Platzbecker - University Hospital Dresden, Germany and Prof Gert Ossenkoppele - VU University Medical Center, Amsterdam, Netherlands )
19 Dec 2013

2013 ecancermedicalscience article highlights

Prof Gordon McVie - ecancer and European Institute of Oncology
2013 ecancermedicalscience article highlights ( Prof Gordon McVie - ecancer and European Institute of Oncology )
11 Dec 2013

Chimeric antigen receptor produces complete responses and long-term persistence in children and adults relapsed, refractory ALL

Dr. Stephen A. Grupp - University of Pennsylvania, Philadelphia, USA
Chimeric antigen receptor produces complete responses and long-term persistence in children and adults relapsed, refractory ALL ( Dr. Stephen A. Grupp - University of Pennsylvania, Philadelphia, USA )
8 Dec 2013

In vitro and in vivo assessment of anfibatide, a novel glycoprotein ib antagonist

Dr Neyu Ni - University of Toronto, Canada
In vitro and in vivo assessment of anfibatide, a novel glycoprotein ib antagonist ( Dr Neyu Ni - University of Toronto, Canada )
8 Dec 2013

Cancer cells and the immune system: a natural story?

Prof. Laurence Zitvogel - INSERM, Institut Gustave Roussy, Villejuif, France
Cancer cells and the immune system: a natural story? ( Prof. Laurence Zitvogel - INSERM, Institut Gustave Roussy, Villejuif, France )
3 Dec 2013

Immuno-Oncology: the next new paradigm in cancer treatment? Chairman's welcome and introduction

Prof. Winald Gerritsen - Radboud University Nijmegen Medical Centre, The Netherlands
Immuno-Oncology: the next new paradigm in cancer treatment? Chairman's welcome and introduction ( Prof. Winald Gerritsen - Radboud University Nijmegen Medical Centre, The Netherlands )
3 Dec 2013

Immuno-Oncology: a concept or already a reality?

Prof. Peter Johnson - Cancer Research UK Centre, University of Southampton, UK
Immuno-Oncology: a concept or already a reality? ( Prof. Peter Johnson - Cancer Research UK Centre, University of Southampton, UK )
3 Dec 2013

Why are Immuno-Oncology compounds different?

Prof. Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain
Why are Immuno-Oncology compounds different? ( Prof. Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain )
3 Dec 2013

Engineering of polymeric nanoparticles for medical applications

Dr Omid Farokhzad - Harvard Medical School, Boston, USA
Engineering of polymeric nanoparticles for medical applications ( Dr Omid Farokhzad - Harvard Medical School, Boston, USA )
14 Nov 2013